Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis
For severe acute pancreatitis (SAP), the combination of urinastatin and octreotide (OCT) is increasingly used. This meta-analysis assesses whether the combination therapy of urinastatin and OCT is more effective than using sole OCT in treating SAP. After searching 12 databases in English and Chinese...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2025-06-01
|
| Series: | Journal of Pancreatology |
| Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850207810375122944 |
|---|---|
| author | Siyao Zeng Yue Li Lianghe Wen Yunlong Li Zhipeng Yao Yang Cao Ming Li Hongliang Wang Junbo Zheng |
| author_facet | Siyao Zeng Yue Li Lianghe Wen Yunlong Li Zhipeng Yao Yang Cao Ming Li Hongliang Wang Junbo Zheng |
| author_sort | Siyao Zeng |
| collection | DOAJ |
| description | For severe acute pancreatitis (SAP), the combination of urinastatin and octreotide (OCT) is increasingly used. This meta-analysis assesses whether the combination therapy of urinastatin and OCT is more effective than using sole OCT in treating SAP. After searching 12 databases in English and Chinese as well as 2 clinical trial centers up to October 7, 2023, we compared the combination of urinastatin and OCT with sole OCT in treating SAP. Statistical measures utilized include risk ratios (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI). We summarized 145 studies from 145 hospitals in 26 provinces, municipalities, and autonomous regions of China, including 13,605 patients. It was found that for SAP, using urinastatin combined with OCT compared to using sole OCT can improve the total effective rate (I2 = 0%; RR: 1.22; 95% CI: 1.19–1.24; P < .01), reduce mortality rate (I2 = 0%; RR: 0.21; 95% CI: 0.09–0.46; P < .01), and reduce the overall incidence rate of complications (I2 = 0%; RR: 0.28; 95% CI: 0.23–0.34; P < .01). In addition, combination therapy reduced in-hospital length of stay, abdominal pain relief time, time for blood and urine amylase to return to normal, inflammatory markers, and improved oxidative stress indicators, immune function indicators, and hemorheology indicators. Low-quality evidence suggests that for SAP, the combined use of urinastatin and OCT may be associated with better improvement in patient’s symptoms, signs, computed tomography (CT) imaging manifestations, and laboratory indicators such as inflammatory markers, oxidative stress markers, immune function indicators, and hemorheological indicators compared to using OCT alone. Additionally, the combination therapy compared to monotherapy may also be associated with lower mortality, a reduced incidence rate of complications, and a shorter in-hospital length of stay. Future research calls for multicenter, high-quality, well-designed studies to validate our findings. |
| format | Article |
| id | doaj-art-a72695e3a37f4b8d9d159dfb63d5b6a3 |
| institution | OA Journals |
| issn | 2096-5664 2577-3577 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Journal of Pancreatology |
| spelling | doaj-art-a72695e3a37f4b8d9d159dfb63d5b6a32025-08-20T02:10:24ZengWolters Kluwer Health/LWWJournal of Pancreatology2096-56642577-35772025-06-018210611710.1097/JP9.0000000000000181202506000-00005Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysisSiyao Zeng0Yue Li1Lianghe Wen2Yunlong Li3Zhipeng Yao4Yang Cao5Ming Li6Hongliang Wang7Junbo Zheng8a Harbin Medical University Graduate School, Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, Chinab Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, ChinaFor severe acute pancreatitis (SAP), the combination of urinastatin and octreotide (OCT) is increasingly used. This meta-analysis assesses whether the combination therapy of urinastatin and OCT is more effective than using sole OCT in treating SAP. After searching 12 databases in English and Chinese as well as 2 clinical trial centers up to October 7, 2023, we compared the combination of urinastatin and OCT with sole OCT in treating SAP. Statistical measures utilized include risk ratios (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI). We summarized 145 studies from 145 hospitals in 26 provinces, municipalities, and autonomous regions of China, including 13,605 patients. It was found that for SAP, using urinastatin combined with OCT compared to using sole OCT can improve the total effective rate (I2 = 0%; RR: 1.22; 95% CI: 1.19–1.24; P < .01), reduce mortality rate (I2 = 0%; RR: 0.21; 95% CI: 0.09–0.46; P < .01), and reduce the overall incidence rate of complications (I2 = 0%; RR: 0.28; 95% CI: 0.23–0.34; P < .01). In addition, combination therapy reduced in-hospital length of stay, abdominal pain relief time, time for blood and urine amylase to return to normal, inflammatory markers, and improved oxidative stress indicators, immune function indicators, and hemorheology indicators. Low-quality evidence suggests that for SAP, the combined use of urinastatin and OCT may be associated with better improvement in patient’s symptoms, signs, computed tomography (CT) imaging manifestations, and laboratory indicators such as inflammatory markers, oxidative stress markers, immune function indicators, and hemorheological indicators compared to using OCT alone. Additionally, the combination therapy compared to monotherapy may also be associated with lower mortality, a reduced incidence rate of complications, and a shorter in-hospital length of stay. Future research calls for multicenter, high-quality, well-designed studies to validate our findings.http://journals.lww.com/10.1097/JP9.0000000000000181 |
| spellingShingle | Siyao Zeng Yue Li Lianghe Wen Yunlong Li Zhipeng Yao Yang Cao Ming Li Hongliang Wang Junbo Zheng Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis Journal of Pancreatology |
| title | Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis |
| title_full | Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis |
| title_fullStr | Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis |
| title_full_unstemmed | Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis |
| title_short | Urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis: a meta-analysis |
| title_sort | urinastatin combined with octreotide versus sole octreotide in severe acute pancreatitis a meta analysis |
| url | http://journals.lww.com/10.1097/JP9.0000000000000181 |
| work_keys_str_mv | AT siyaozeng urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT yueli urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT lianghewen urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT yunlongli urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT zhipengyao urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT yangcao urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT mingli urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT hongliangwang urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis AT junbozheng urinastatincombinedwithoctreotideversussoleoctreotideinsevereacutepancreatitisametaanalysis |